Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Lessons of the month 2: A case of inappropriate drug–drug interaction in kidney transplant

Min-Hui Tan, Seow-Yeing Yee and Rosnawati Yahya
Download PDF
DOI: https://doi.org/10.7861/clinmed.2021-0789
Clin Med March 2022
Min-Hui Tan
Aconsultant nephrologist, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Roles: consultant nephrologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tanminhui83@yahoo.com
Seow-Yeing Yee
Aconsultant nephrologist, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Roles: consultant nephrologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosnawati Yahya
Aconsultant nephrologist, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Roles: consultant nephrologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

Carbamazepine remains a first-line antiepileptic medication for the treatment of partial seizures. Despite its widespread use, carbamazepine has significant neurotoxicity and hypersensitivity reactions. We report a case of a patient post-kidney transplant who was on regular carbamazepine for childhood epilepsy and developed nystagmus, diplopia and a broad-base gait after receiving diltiazem. Understanding of the interaction between diltiazem and carbamazepine is necessary to prevent the neurotoxic effects.

KEYWORDS:
  • carbamazepine
  • diltiazem
  • drug interaction
  • kidney transplant
  • neurotoxicity

Introduction

Carbamazepine is a commonly used first-line agent for treatment of epilepsy. However, it can cause significant neurotoxicity and hypersensitivity reactions due to high concentrations of its active metabolite in response to co-administration of other medications. Here, we report a case of inappropriate co-administration of diltiazem leading to carbamazepine toxicity in a patient post-kidney transplant.

Case presentation

A 49-year-old man was admitted urgently for symptoms of lethargy, tinnitus and blurring of vision over 4 days. He was a recipient of a living-unrelated kidney transplant 27 years ago with his primary renal disease being lupus nephritis. His other medical history included childhood epilepsy, hypertension, old lacunar infarct and history of pulmonary tuberculosis (in which he had completed treatment 11 years previously).

He was a chronic smoker of 1 pack per day. He denied any allergies. His medications were prednisolone, cyclosporin, carbamazepine, sodium valproate, metoprolol, felodipine, Cardiprin and simvastatin. He claimed compliant to these medications.

A week prior to this, he was admitted for acute allograft dysfunction (his creatinine level rose from 186 to 236 µmol/L). His allograft biopsy showed borderline rejection for which he received intravenous methylprednisolone and his immunosuppression regimen was augmented. His cyclosporin was changed to tacrolimus and felodipine was changed to diltiazem to help achieve adequate trough levels of tacrolimus, as part of cost-saving measures.

During this admission, he was haemodynamically stable and afebrile. His cardiovascular and respiratory examinations were unremarkable. His abdomen was soft with no graft tenderness and there was no organomegaly. He had bilateral bidirectional nystagmus but no papilloedema on funduscopy. His other cranial nerves examination was normal. He had broad-based gait but had no past-pointing, no dysdiadochokinesia and Romberg's test was negative. Examination of his bilateral upper and lower limbs revealed normal tone and power with intact reflexes and sensation.

Initial differential diagnoses included central nervous system pathology or drug toxicity. An urgent computed tomography of the brain showed old lacunar infarcts with no evidence of haemorrhage, thus excluding acute intracranial pathology. A brief review of his blood results revealed normal electrolytes but high trough carbamazepine level. His serial investigations are shown in Table 1. Therefore, he was diagnosed with carbamazepine toxicity due to cytochrome P450 inhibition by co-administration of diltiazem.

View this table:
  • View inline
  • View popup
Table 1.

Serial investigations trend

His carbamazepine was withheld for a day and restarted at lower dose after that. The neurological symptoms improved during the hospital stay after reduction of carbamazepine dose, and he was discharged well with regular therapeutic drug monitoring. His visual impairment and tinnitus resolved completely during the outpatient clinic review.

Discussion

Tacrolimus has become a central part of the modern immunosuppression regimen for kidney transplants since the publication of the ELITE SYMPHONY trial.1 Despite its high intra- and inter-individual variability, the high cost of tacrolimus puts tremendous pressure on the healthcare expenditure. Administration of diltiazem is known to increase concentrations of tacrolimus in kidney transplant recipients, thus resulting in a tacrolimus-sparing effect. This occurs via two mechanisms, namely either through diltiazem-induced inhibition of cytochrome P450 3A4-mediated presystemic tacrolimus metabolism or through inhibition of transport by P-glycoprotein.2,3

Using diltiazem to minimise the dose of tacrolimus has been recommended in the Kidney Disease: Improving Global Outcomes (KDIGO) 2009 guidelines, as part of the strategies to reduce drug costs.4 This has been proven to be effective in our local transplant setting. Co-administration of tacrolimus and diltiazem has also been shown to have a relatively safe adverse effect profile.5 As part of the treatment of borderline rejection in our patient, the immunosuppressive regimen has been optimised with co-administration of tacrolimus and diltiazem.

Unfortunately, our patient developed central nervous system (CNS) side effects that were attributed to carbamazepine toxicity, after excluding acute organic causes. Reduction of carbamazepine dose in this patient resulted in reversal of the neurological symptoms; thus, confirming the diagnosis.

Carbamazepine is largely protein-bound and its plasma half-life ranges from 30 to 40 hours. Co-administration of diltiazem is also known to inhibit carbamazepine metabolism via the cytochrome P450 pathway. Clinical features of carbamazepine toxicity include nystagmus, diplopia, ataxia, CNS depression, respiratory failure, seizures, cardiac arrhythmias and hypotension. There is no antidote for carbamazepine toxicity as the mainstay of management is supportive therapy. Haemodialysis or peritoneal dialysis have limited efficacy due to its high plasma protein binding and large volume of distribution.6,7

Adverse drug–drug interactions have a significant impact on healthcare systems, leading to as high as 21% of hospital admission as well as a major cause of mortality. The incidence is rising, owing to polypharmacy practices and newer drugs with a relatively poorly understood metabolism. Other factors that increase risks of interactions include interference of absorption of certain medicines in the gut and impaired renal function leading to poor clearance; for example, iron supplements are known to interfere with absorption of fluoroquinolones and tetracycline antibiotics. Meanwhile, elimination of the active form of morphine (morphine-6-glucuronide) is dependent on glomerular filtration.8

While it is impossible to remember all potentially life-threatening drug–drug interactions, a prescriber should strive to check all new prescriptions to consider for potential interactions. If a therapeutic drug monitoring service is available for medicines of concern, this should be utilised as well. The role of dedicated transplant pharmacists is crucial to counter-check individual prescriptions and such a service should ideally be available in every transplant centre.

Conclusion

Drug–drug interactions represent a common clinical problem in the management of a patient with complicated kidney transplant from multiple comorbidities. This case demonstrated that, although inhibition of tacrolimus metabolism with diltiazem helps with cost-saving, this unfortunately led to unwanted carbamazepine toxicity. Increased clinical vigilance will help avoid this adverse interaction.

Acknowledgements

We would like to thank the director general of health Malaysia for his permission to publish this article.

  • © Royal College of Physicians 2022. All rights reserved.

References

  1. ↵
    1. Ekberg H
    , Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med 2007;357:2362–575.
    OpenUrl
  2. ↵
    1. Hebert MF
    , Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999;33:680–2.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Staatz CE
    , Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623–53.
    OpenUrlCrossRefPubMed
  4. ↵
    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:S1–155.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chong CL
    , Wong HS, Lee FY, et al. Dose response relationship between diltiazem and tacrlimus and its safety in renal transplant recipients. Transplant Proc 2018;50:2515–20.
    OpenUrl
  6. ↵
    1. Duzova A
    , Baskin E, Usta Y, Ozen S. Carbamazepine poisoning: treatment with plasma exchange. Hum Exp Toxicol 2001;20:175–7.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Goktas U
    , Kati I, Yuce HH. Management of a severe carbamazepine overdose with continuous venovenous hemodiafiltration. Am J Emerg Med 2010;28:260.e1–2.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Day RO
    , Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. Intern Med J 2017;47:501–12.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Lessons of the month 2: A case of inappropriate drug–drug interaction in kidney transplant
Min-Hui Tan, Seow-Yeing Yee, Rosnawati Yahya
Clinical Medicine Mar 2022, 22 (2) 169-171; DOI: 10.7861/clinmed.2021-0789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lessons of the month 2: A case of inappropriate drug–drug interaction in kidney transplant
Min-Hui Tan, Seow-Yeing Yee, Rosnawati Yahya
Clinical Medicine Mar 2022, 22 (2) 169-171; DOI: 10.7861/clinmed.2021-0789
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Introduction
    • Case presentation
    • Discussion
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Lessons of the month 1: Shoshin beriberi: A case report of fulminant cardiovascular collapse, intractable hyperlactatemia and deteriorating consciousness
  • Lessons of the month 2: Retinal vasculitis: a first presentation of Takayasu's arteritis
Show more Lessons of the month

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians